Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
CAMBRIDGE, Mass., March 03, 2016 -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the Cowen &Company 36th Annual Health Care Conference, taking place March 7-9 at the Boston Marriott Copley Place.
| Cowen & Company 36th Annual Health Care Conference -- CoLucid Presentation Details | |
| Date: | Tuesday, March 8 |
| Time: | 8:40am – 9:10am Eastern Time |
| Location: | Boston Marriott Copley Place, Berkeley Room, 3rd Floor |
| Webcast: | http://wsw.com/webcast/cowen30/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing oral lasmiditan for the acute treatment of migraine in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (781) 365-2596 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
